Literature DB >> 15197349

Interference of glucocorticoids with apoptosis signaling and host-tumor interactions.

Hans Peter Rutz1, Ingrid Herr.   

Abstract

The cure of cancer is compromised by a variety of factors and mechanisms, which include tissue origin of the malignant cells, tumor load and hypoxia, impediment of drug access, and cellular resistance to treatment. Treatment resistance may be intrinsic, acquired, or induced, and it may occur to either radiation or a single drug alone, or simultaneously to multiple agents. Although the problem of corticosteroid-induced and hence, iatrogenic resistance to the treatment of cancer has continuously gained some interest over the past several years, no measures have been taken yet to diligently examine this problem in the clinical situation. In this review, we address several additional mechanisms through which glucocorticoids may influence the result of cytotoxic therapy of cancer, like: inducible interference of with apoptosis signaling; interference with immune response against malignant cells; issues relating to their impact on glucose metabolism in cancer patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15197349     DOI: 10.4161/cbt.3.8.966

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  14 in total

1.  Corticosterone influences gerbil (Meriones unguiculatus) prostatic morphophysiology and alters its proliferation and apoptosis rates.

Authors:  Julia Quilles Antoniassi; Ricardo Alexandre Fochi; Rejane Maira Góes; Patricia Simone Leite Vilamaior; Sebastião Roberto Taboga
Journal:  Int J Exp Pathol       Date:  2017-06-29       Impact factor: 1.925

2.  Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug.

Authors:  Samaresh Sau; Sujan Kumar Mondal; Sushil K Kashaw; Arun K Iyer; Rajkumar Banerjee
Journal:  Mol Cell Biochem       Date:  2017-06-05       Impact factor: 3.396

Review 3.  Tumor Suppressive Effects of GAS5 in Cancer Cells.

Authors:  Jesminder Kaur; Nur'ain Salehen; Anwar Norazit; Amirah Abdul Rahman; Nor Azian Abdul Murad; Nik Mohd Afizan Nik Abd Rahman; Kamariah Ibrahim
Journal:  Noncoding RNA       Date:  2022-05-28

Review 4.  Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.

Authors:  Alex Gutierrez-Dalmau; Josep M Campistol
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Dexamethasone inhibits camptothecin-induced apoptosis in C6-glioma via activation of Stat5/Bcl-xL pathway.

Authors:  Yi-Hua Qian; Qingli Xiao; Hong Chen; Jan Xu
Journal:  Biochim Biophys Acta       Date:  2009-02-07

6.  Dexamethasone acts as a radiosensitizer in three astrocytoma cell lines via oxidative stress.

Authors:  Sylvia Ortega-Martínez
Journal:  Redox Biol       Date:  2015-06-23       Impact factor: 11.799

7.  Dexamethasone enhances programmed cell death 1 (PD-1) expression during T cell activation: an insight into the optimum application of glucocorticoids in anti-cancer therapy.

Authors:  Kailin Xing; Bingxin Gu; Ping Zhang; Xianghua Wu
Journal:  BMC Immunol       Date:  2015-06-26       Impact factor: 3.615

8.  Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts and established cell lines of pancreatic cancer.

Authors:  Chengwen Zhang; Armin Kolb; Peter Büchler; Andrew C B Cato; Jürgen Mattern; Werner Rittgen; Lutz Edler; Klaus-Michael Debatin; Markus W Büchler; Helmut Friess; Ingrid Herr
Journal:  BMC Cancer       Date:  2006-03-15       Impact factor: 4.430

9.  Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo.

Authors:  N Gassler; C Zhang; T Wenger; P A Schnabel; H Dienemann; K-M Debatin; J Mattern; I Herr
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

10.  Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas.

Authors:  Sarah K Knutson; Natalie M Warholic; L Danielle Johnston; Christine R Klaus; Tim J Wigle; Dorothy Iwanowicz; Bruce A Littlefield; Margaret Porter-Scott; Jesse J Smith; Mikel P Moyer; Robert A Copeland; Roy M Pollock; Kevin W Kuntz; Alejandra Raimondi; Heike Keilhack
Journal:  PLoS One       Date:  2014-12-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.